A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.
about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlCardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsPreclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.Obesity-Related Hormones in Low-Income Preschool-Age Children: Implications for School Readiness.Diabetes and cardiovascular disease: the potential benefit of incretin-based therapiesSelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesEffects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitusNative incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.Pleiotropic effects of incretinsExendin-4 protects HUVECs from t-BHP-induced apoptosis via PI3K/Akt-Bcl-2-caspase-3 signaling.The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.PAI-1 and diabetes: a journey from the bench to the bedside.Cardiovascular biology of the incretin system.Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).Protective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative DamageAlleviation of hyperglycemia induced vascular endothelial injury by exenatide might be related to the reduction of nitrooxidative stress.Add-on therapies to metformin for type 2 diabetes.Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.Cardiovascular effects of incretin-based therapies.The effect of glucagon-like peptide 1 on cardiovascular risk.Potential cardiovascular effects of incretin-based therapies.Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?GLP-1 receptor agonists: effects on cardiovascular risk reduction.Direct cardiovascular effects of glucagon like peptide-1.Antidiabetic agents and endothelial dysfunction - beyond glucose control.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.Understanding the cardiovascular effects of incretin.A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
P2860
Q26740443-488CB2B0-CA00-43B0-9E72-FF1B83CF0D1AQ26750746-26C3881D-A994-48BF-A42E-CE172D1247D6Q26752255-E3EA8AF3-E23E-42F0-9F5B-13DF09A6A468Q26823085-1621C79C-1AAF-4E84-A9F8-12D02917B86FQ33521451-DEDDB3A8-6E04-4876-9933-A0046C75358DQ33603384-F9103180-44C7-4881-9BB2-5185373F8807Q33656442-700566A9-8D2C-416D-8086-7939DDB19BB3Q33755744-39C61870-5E33-45AF-B6D9-CA885D666B7FQ34290086-41DC7B3C-A7E0-4072-87D4-CF49E8AC5BABQ34716791-10E0C5C7-EE9E-4299-A4FB-5ABEE7A0F46CQ34994502-4BA20228-F261-4C5B-B09B-B54E24D53711Q35117779-F1441CCD-11E8-4D8A-B1EC-E7EA21F3C48AQ35201564-32340E08-A870-4594-A615-67233A58B904Q35784692-999C97BF-76FF-4FA7-9DB3-83D6EF94D060Q35936644-F6CA6C54-7645-4C94-86D6-B9F8D2176715Q35968092-CA5B7D43-B149-4BBA-B8A2-7EA9B220DB74Q35974766-EAE2A050-1CA6-480D-8512-638D7D454559Q36063048-7B16A712-EC58-4268-A45B-5B6BB34CCB3DQ36249561-B7791F9D-8514-4CCF-8307-FB6345E4E179Q36484283-2944EF45-7F30-445D-8DE1-191DDFB454DFQ36935346-9A949937-2D56-463F-B1AF-D9AE9695F2ABQ37177528-CDF795F5-76B4-44DD-A757-B7E3942E44DFQ37235840-9472E1E1-1D81-4B77-94D8-99EFFE02CFA5Q37328568-5FFD8CC8-AA35-4055-BD71-CCBB78BDFDC7Q37382874-E374445A-8C1D-46B6-A409-3C47D623AE62Q37818234-035BB903-0D31-44D1-BAD4-516B5C18989FQ37825946-0D446F9D-4749-47DB-A1AF-99E9009CE046Q37872358-D88FD29F-A4A6-42AB-9BA7-B913DC829930Q37977336-346BF206-E6A8-4830-A14B-EFC3D80D3718Q37980019-85F199B2-3EEF-4A2A-936F-1DFCCEC9C128Q37990619-3C7BDAA8-6AC5-49DB-9A5E-F2CAC9536463Q38005223-E217F53F-CCA8-49F8-9058-F1EB06250A5EQ38122396-4B1A8FDD-684F-4A6D-BF83-432421B27B81Q38132470-D7F0DDFF-BD78-442A-A37C-08E92F7A736CQ38397635-A2E817BA-D8AE-4E48-BCCC-14AFEFDDA0A6Q38524435-5D2D6B64-69D2-4C51-A101-50A0EEA06557Q38702260-6ABE0431-1EC3-4ECC-A7E2-A0DF81DEFA68Q39260864-E2B2B86C-E09C-4F74-8755-F5D0FBEE6372Q39544576-454A1B36-2551-4F71-BA73-20C8937AB462Q39604870-DD7C6622-4D0B-4989-A8A9-3074EE543D19
P2860
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@en
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@nl
type
label
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@en
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@nl
prefLabel
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@en
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@nl
P2093
P356
P1476
A long-acting glucagon-like pe ...... d vascular adhesion molecules.
@en
P2093
Hongbin Liu
Lotte B Knudsen
Richard W Simpson
P356
10.1677/JOE-08-0468
P407
P577
2009-01-09T00:00:00Z